alfimeprase
Recombinant proteinexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
7
Phase 3
4
Phase 4
0
Earliest trial started Jun 1, 2003 (NCT00073554)
Timeline
Indications
Mechanism of action
- FibrinogenHYDROLYTIC ENZYME
Fibrinogen hydrolytic enzyme
- Urokinase-type plasminogen activatorSupplementation
PLAU supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108893 ↗
Also known as
- alfimeprase
- alfimeprase
- alfimeprase
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00499902 | Phase 2 | Jun 1, 2007 | Arca Biopharma, Inc. |
| NCT00338585 | Phase 3 | Apr 1, 2006 | Arca Biopharma, Inc. |
| NCT00322270 | Phase 3 | Jan 1, 2006 | Arca Biopharma, Inc. |
| NCT00346424 | Phase 3 | Sep 1, 2005 | Arca Biopharma, Inc. |
| NCT00115999 | Phase 3 | Apr 1, 2005 | Arca Biopharma, Inc. |
| NCT00073515 | Phase 2 | Nov 21, 2003 | Arca Biopharma, Inc. |
| NCT00073554 | Phase 2 | Jun 1, 2003 | Arca Biopharma, Inc., Health Decisions |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arca Biopharma, Inc. | For profit | 7 | 7 | 2 | 2003 |
| Health Decisions | For profit | 1 | 0 | 1 | 2003 |
2 organizations
Page 1 / 1